Steris Corp (STE) Received its Third Buy in a Row


After Stephens and KeyBanc gave Steris Corp (NYSE: STE) a Buy rating last month, the company received another Buy, this time from Northcoast Research. Analyst David Keiser reiterated a Buy rating on Steris Corp today and set a price target of $127. The company’s shares opened today at $114.74, close to its 52-week high of $117.48.

According to TipRanks.com, Keiser is a 4-star analyst with an average return of 16.8% and a 81.6% success rate. Keiser covers the Healthcare sector, focusing on stocks such as Wright Medical Group, Stryker Corporation, and Cooper Co.

Steris Corp has an analyst consensus of Strong Buy, with a price target consensus of $124, implying an 8.1% upside from current levels. In a report released yesterday, Stephens also reiterated a Buy rating on the stock with a $125 price target.

.

See today’s analyst top recommended stocks >>

Steris Corp’s market cap is currently $9.61B and has a P/E ratio of 33.35. The company has a Price to Book ratio of 3.00.

Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

STERIS Plc engages in the provision of infection prevention and other procedural products and services. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts